An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures
Public ClinicalTrials.gov record NCT04686786. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 57-Week, Multicenter, Active-treatment, Open-label Extension Trial of CVL-865 as Adjunctive Therapy in Adults With Drug-Resistant Focal Onset Seizures
Study identification
- NCT ID
- NCT04686786
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 105 participants
Conditions and interventions
Conditions
Interventions
- CVL-865 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 7, 2020
- Primary completion
- Dec 4, 2024
- Completion
- Dec 4, 2024
- Last update posted
- Dec 10, 2025
2020 – 2024
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Little Rock, Arkansas | Little Rock | Arkansas | 72205 | — |
| New Haven, Connecticut | New Haven | Connecticut | 06519 | — |
| Gulf Breeze, Florida | Gulf Breeze | Florida | 32561-4458 | — |
| Jacksonville, Florida | Jacksonville | Florida | 32224 | — |
| Miami Lakes, Florida | Miami Lakes | Florida | 33016 | — |
| Orlando, Florida | Orlando | Florida | 32806 | — |
| Port Charlotte, Florida | Port Charlotte | Florida | 33952 | — |
| Tampa, Florida | Tampa | Florida | 33606 | — |
| Honolulu, Hawaii | Honolulu | Hawaii | 96817 | — |
| Lexington, Kentucky | Lexington | Kentucky | 40504 | — |
| Scarborough, Maine | Scarborough | Maine | 04074 | — |
| Baltimore, Maryland | Baltimore | Maryland | 21287 | — |
| Bethesda, Maryland | Bethesda | Maryland | 20817 | — |
| Boston, Massachusetts | Boston | Massachusetts | 02114 | — |
| Chesterfield, Missouri | Chesterfield | Missouri | 63005 | — |
| Saint Louis, Missouri | St Louis | Missouri | 63110 | — |
| Hackensack, New Jersey | Hackensack | New Jersey | 07601 | — |
| New York | New York | New York | 10021 | — |
| Rochester, New York | Rochester | New York | 14642 | — |
| Toledo, Ohio | Toledo | Ohio | 43614 | — |
| Oklahoma City, Oklahoma | Oklahoma City | Oklahoma | 73112 | — |
| Philadelphia, Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Philadelphia, Pennsylvania | Philadelphia | Pennsylvania | 19107 | — |
| Charleston, South Carolina | Charleston | South Carolina | 29425 | — |
| Nashville, Tennessee | Nashville | Tennessee | 37232 | — |
| Salt Lake City, Utah | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04686786, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2025 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04686786 live on ClinicalTrials.gov.